GLP-1 patient assistance: every cost-reduction pathway available in 2026

TLDR. Beyond NovoCare and LillyDirect, GLP-1 patients have several rarely-discussed assistance paths: Novo Nordisk Patient Assistance Program (free Ozempic or Wegovy for income-qualifying uninsured patients), Lilly Cares (free Mounjaro or Zepbound for similar criteria), 340B clinic access (some FQHCs dispense at discounted prices), manufacturer copay cards (down to $25/mo for commercial insurance patients), and 503B compounding routes for some indications. Patient Advocate Foundation and NeedyMeds maintain searchable databases. Most patients qualify for at least one program; few know to apply.

The standard advice for cash-pay GLP-1 is "NovoCare for Wegovy at $199-$399, LillyDirect for Zepbound at $299-$449 or compounded semaglutide at $99-$249." Those are real and we cover them in detail. But there are additional cost-reduction pathways that get less coverage. For patients near or under the federal poverty line, these pathways are the difference between affording GLP-1 long-term and not.

Manufacturer copay cards (with insurance)

Both Novo Nordisk and Eli Lilly offer copay-assistance cards that cap out-of-pocket cost for insured patients regardless of plan formulary:

• Wegovy SavingsCard: up to $200 off per monthly fill, $1,800 maximum per year. Requires commercial insurance (not Medicare or Medicaid). Apply at NovoCare.
• Zepbound Savings Card: up to $469 off per monthly fill if your plan does not cover. If your plan covers Zepbound, max copay is $25/month with the card.

These cards combine with insurance. So They reduce your copay even after a successful PA. The combination of in-network coverage plus the manufacturer card often gets the monthly cost down to $25 or less.

NovoCare and LillyDirect direct-to-consumer programs

Both manufacturers run cash-pay direct programs for uninsured or coverage-excluded patients:

• NovoCare for Wegovy: $199-$399/month depending on dose tier, billed direct to patient. No insurance required. Shipped from NovoCare's preferred pharmacy.
• LillyDirect for Zepbound: $299-$449/month depending on dose, as single-dose vials or the multi-dose KwikPen at the same price. Cash-pay direct. No insurance required.

These are the cheapest brand-medication paths if you don't have insurance coverage. They require a prescription from a licensed telehealth provider; the programs in our chart at best for cash-pay can write the script.

340B clinics

340B is a federal program that allows safety-net clinics (FQHCs, Ryan White HIV clinics, certain hospitals) to acquire medications at discounted prices. 340B-eligible clinics can dispense GLP-1 medications to qualifying patients at significantly reduced cost.

Find a 340B clinic in your state: HRSA maintains a public 340B Database. If you're below 200% of the federal poverty line and live near an FQHC, this can be the cheapest legitimate path.

The trade-off: 340B clinics have longer wait times, less digital convenience and limited dose flexibility. For low-income patients, the savings make it worth navigating.

Compounded GLP-1 economics

503A and 503B compounded semaglutide remains the cheapest cash-pay path in 2026 for most patients. Typical pricing:

• 503A compounded semaglutide: $99-$249/month (varies by pharmacy and dose)
• 503A compounded tirzepatide: $199-$349/month (rarer, regulatory exposure)

The regulatory environment has tightened since the FDA removed semaglutide from the official shortage list in February 2025. Most 503A pharmacies now compound under the personalized-formulation framework (with added vitamin B12 or similar). See our compounded breakdown for the regulatory context.

HSA and FSA reimbursement

GLP-1 medications prescribed for an FDA-approved indication (chronic weight management, type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, MASH) are eligible HSA and FSA expenses. Most programs in our chart will provide an itemized receipt for HSA/FSA submission. Off-label uses (PCOS, fertility preparation, post-bariatric regain) are typically also eligible but check with your plan administrator.

For patients with high-deductible plans plus HSA, the math often favors HSA cash-pay over running a PA: you pay full cost out of your HSA pre-tax. That is roughly equivalent to a 25-37% discount on the cash-pay price.

State-specific assistance

Several states run their own pharmaceutical assistance programs that may cover GLP-1:

• New York (EPIC): Medicare-eligible patients age 65+ at certain income levels
• New Jersey (PAAD/Senior Gold): Medicare-eligible 65+ at income limits
• Pennsylvania (PACE/PACENET): Medicare-eligible 65+ at income limits
• Other states have similar programs at various coverage levels

For state-by-state pharmaceutical assistance programs, search "[your state] pharmaceutical assistance" or check the National Conference of State Legislatures pharmaceutical assistance database.

If nothing works: the realistic floor

If insurance won't cover, manufacturer cards don't apply, you're not 340B-eligible and you can't access state programs, the realistic floor for cash-pay GLP-1 in 2026 is roughly $99/month for compounded oral semaglutide (Strut Health and similar) or $178/month for compounded injectable semaglutide flat-rate (Mochi).

Below that, the math doesn't currently work in the US market. Microdose protocols can stretch a $99 supply over 2-3 months for some patients, effectively dropping cost to $33-$50/month, but this is off-label and we don't recommend it without clinical supervision.

For the cheapest predictable cash-pay paths, see our under-$150 rankings or the cheapest GLP-1 programs.

Frequently asked questions

What is the Novo Nordisk Patient Assistance Program?

Free Wegovy or Ozempic for income-qualifying uninsured patients. Income ceiling is typically up to 400 percent of the federal poverty level (around $58,000 for a household of one in 2026, higher for larger households). Application requires prescriber paperwork, proof of income, and US citizenship or permanent residency. Approval timeline is 2 to 6 weeks.

What is Lilly Cares?

The Eli Lilly equivalent of Novo PAP. Free Mounjaro or Zepbound for similar income criteria. Application process is similar: prescriber paperwork, income proof, citizenship. Eligibility rules and approval timelines vary slightly from Novo. The application is available at lillycares.com.

Can I use a manufacturer copay card?

Yes, if you have commercial insurance and the medication is covered. Wegovy and Zepbound both offer savings cards that can reduce copays to as low as $25/month for commercial-insured patients with PA approval. Copay cards do not stack with government insurance (Medicare, Medicaid, VA, TRICARE). For the full list of savings cards, manufacturer direct-cash programs, and the Medicare Bridge, see the GLP-1 coupons and savings guide.

What is 340B and how does it help with GLP-1 cost?

340B is a federal program that lets qualifying clinics (Federally Qualified Health Centers, Ryan White clinics, others) buy outpatient medications at reduced prices. Some FQHCs pass the savings to patients, with GLP-1 cash prices sometimes 50 to 80 percent below retail. Eligibility requires using the clinic as your primary care provider; the discount is not universally available.

Where do I find all the assistance programs I might qualify for?

Two free resources. Patient Advocate Foundation offers case management for assistance navigation (patientadvocate.org). NeedyMeds maintains a searchable database of patient assistance programs, copay cards, and disease-specific funds (needymeds.org). Plug in 'semaglutide' or 'tirzepatide' to see all options.